The inactivation, mutation, or loss of NF2 in meningiomas leads to loss of NF2 tumor suppressor activity, most notably by way of altered E-Cadherin expression, CD44-mediated cell–cell contact inhibition, and the Hippo signaling pathway. Here, CD44 is linked to meningioma.